Oncologists report high career satisfaction

Oncologists report high career satisfaction
Oncologists are overall very satisfied with their careers, according to a study published online Jan. 27 in the Journal of Clinical Oncology.

(HealthDay)—Oncologists are overall very satisfied with their careers, according to a study published online Jan. 27 in the Journal of Clinical Oncology.

Tait D. Shanafelt, M.D., from the Mayo Clinic in Rochester, Minn., and colleagues surveyed U.S. oncologists (1,117 completed full length surveys; 49.6 percent women) to evaluate burnout and career satisfaction at all career stages.

The researchers found that 33.8 percent of the respondents were in academic practice (AP) and 43.2 percent were in private practice (PP). On average, oncologists worked 57.6 hours per week (AP, 58.6 hours per week; PP, 62.9 hours per week) and saw a mean of 52 outpatients per week. Based on the emotional exhaustion and/or depersonalization domain of Maslach Burnout Inventory, 44.7 percent of oncologists were burned out (AP, 45.9 percent; PP, 50.5 percent; P = 0.18). In univariate and multivariate analyses, the primary professional predictor of burnout for both PP and AP oncologists was hours per week devoted to direct patient care. While the majority of oncologists in AP and PP were satisfied with their career (82.5 percent) and specialty (80.4 percent) choices, these measures were lower for those in PP than those in AP (all P < 0.006).

"Those oncologists who devote the greatest amount of their professional time to patient care seem to be at greatest risk for burnout," the authors write.

More information: Abstract
Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Survey finds symptoms of burnout common among US physicians

Aug 20, 2012

A national survey of 7,288 physicians (26.7 percent participation rate) finds that 45.8 percent of physicians reported at least one symptom of burnout, according to a report published Online First by Archives of Internal Me ...

Recommended for you

Lanreotide improves survival with enteropancreatic tumors

13 hours ago

(HealthDay)—Lanreotide significantly improves survival among patients with metastatic enteropancreatic neuroendocrine tumors (grade 1 or 2), according to a study published in the July 17 issue of the New En ...

User comments